P 151
Alternative Names: P-151Latest Information Update: 18 Sep 2023
At a glance
- Originator Abbisko Therapeutics; Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 06 Sep 2023 Early research in Unspecified in China (unspecified route), prior to September 2023 (Abbisko Therapeutics pipeline, September 2023)
- 06 Sep 2023 Investigation in Unspecified in USA (unspecified route), prior to September 2023 (Abbisko Therapeutics pipeline, September 2023)